Novo Nordisk's $2.6B Bet on Obesity
Novo Nordisk's $2.6B Gamble on Obesity Treatment
Novo Nordisk signs massive $2.6 billion deal with Jiangsu Hengrui Pharmaceuticals for obesity treatment, a high-stakes gamble in the pharmaceutical industry.
Jiangsu Hengrui Pharmaceuticals
1 story on MONEYEDIT.